



11 May 2022
EMA/CVMP/154238/2022
Committee for Veterinary Medicinal Products

Timetable for the procedure

Referral under Article 82 of Regulation (EU) 2019/6

Procedure number: EMEA/V/A/146

Veterinary medicinal products containing N-methyl pyrrolidone as an excipient

Melovem 30 mg/ml solution for injection (EMEA/V/C/000152/A82/0014)

Vectra 3D spot-on solution (EMEA/V/C/002555/A82/0023)

Procedural step:	Date
Notification	3 May 2022
Start of the procedure (CVMP)	May, 2022 CVMP
Rapporteur to circulate assessment report to co-rapporteur and CVMP members	13 June 2022
Critique from co-rapporteur on assessment report	28 June 2022
Peer review comments from CVMP members on assessment report	4 July 2022
Rapporteur to circulate updated assessment report to CVMP members	8 July 2022
CVMP discussion on the rapporteurs' assessment report (<i>clock stop</i>)	13 July 2022
Applicants'/marketing authorisation holders' comments to the rapporteurs' assessment report. Responses to list of questions to stakeholders (<i>clock restart</i>)	13 September 2022
Rapporteur to circulate revised assessment report to co-rapporteur and CVMP members	10 October 2022
Critique from co-rapporteur on assessment report	24 October 2022



Peer review comments from CVMP members on assessment report	31 October 2022
Rapporteur to circulate updated revised rapporteur assessment report to CVMP members	4 November 2022
CVMP discussion on the revised assessment report	9 November 2022
Rapporteur to circulate updated revised assessment report	18 November 2022
Draft CVMP opinion and assessment report to be circulated to CVMP members	29 November 2022
Adoption of CVMP opinion and assessment report	December, 2022 CVMP